title: Detrusor underactivity: Clinical features and pathogenesis of an underdiagnosed geriatric condition.
abstract: Urinary incontinence and other lower urinary tract symptoms exert a major influence on the health and independence of frail older people. Detrusor underactivity (DU) is defined as a contraction of reduced strength and/or duration, resulting in prolonged bladder emptying and/or a failure to achieve complete bladder emptying within a normal time span. DU may influence the clinical presentation and impede the therapy of disorders as common and as disparate as detrusor overactivity, urinary retention, and benign prostatic hyperplasia. Urodynamically, nearly two-thirds of incontinent nursing home residents exhibit DU. The clinical diagnosis of DU when present alone or in association with other bladder conditions such as detrusor overactivity (detrusor hyperactivity with impaired contractility (DHIC)) is challenging, because symptoms lack adequate precision. A catheterized and increasingly noninvasive ultrasound-based postvoid residual assessment allows a bedside diagnosis of retention and may suggest the presence of DU in individuals (mostly women) with a low likelihood of bladder outlet obstruction (BOO). Nevertheless, it cannot differentiate primary DU from retention secondary to BOO. The management of individuals with DHIC remains unsatisfactory, because antispasmodic anticholinergic medications may worsen retention, whereas bethanechol does not improve bladder emptying. Human detrusor biopsies reveal axonal degeneration, muscle loss, and fibrosis in DU. Animal studies suggest that multiple risk factors, including retention itself, lack of estrogen, infection, inflammation, and aging, may contribute to DU. Priority areas for future research include efforts to facilitate clinical nonurodynamic diagnosis of probable DU plus translational research designed to address the pathogenesis of this complex multifactorial geriatric syndrome.
authors.affiliation: Division of Urology, University of Connecticut Health Center, Farmington, Connecticut 06030, USA.
authors.forename: John A
authors.initials: JA
authors.lastname: Taylor
authors.forename: George A
authors.initials: GA
authors.lastname: Kuchel
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D018723:Bethanechol / Q000627:therapeutic use; D005260:Female; D005853:Geriatrics; D006801:Humans; D008297:Male; D008875:Middle Aged; D018721:Muscarinic Agonists / Q000627:therapeutic use; D012307:Risk Factors; D001743:Urinary Bladder / Q000502:physiology* / Q000648:ultrastructure; D053201:Urinary Bladder, Overactive / Q000175:diagnosis* / Q000378:metabolism; D014546:Urinary Catheterization; D014549:Urinary Incontinence / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D016055:Urinary Retention / Q000503:physiopathology* / Q000628:therapy
chemical_list: D018721:Muscarinic Agonists; D018723:Bethanechol